Extractables and Leachables Study Approach for Disposable Materials Used in Bioprocessing - Two case studies illustrate a systematic approach. - BioPharm International

ADVERTISEMENT

Extractables and Leachables Study Approach for Disposable Materials Used in Bioprocessing
Two case studies illustrate a systematic approach.


BioPharm International
Volume 21, Issue 2

CASE STUDY 2: EXTRACTABLES AND LEACHABLES STUDY DESIGN FOR DISPOSABLE TUBING

Like disposable bags, the tubing used in the bioprocess also requires qualification for extractables and leachables. However, because the tubing has a short contact time with the drug product formulation during the manufacturing process, leachables can be evaluated in parallel with a controlled extraction study, as a short-term compatibility study with drug formulation. An E/L study design is presented here.

Step 1: Information Gathering. Information regarding the tubing should be collected in the same manner as for the bag in case study 1. In the present case study, the drug placebo is an aqueous solution, the batch size is 10 liters, and the dosage for the final drug product is a one-milliliter dose at three doses per day.

Step 2: Calculation of Analytical Evaluation Threshold. Based on information collected in Step 1, the AET can be calculated for each extractable per tubing (the SCT of 0.15 g/day is used here per PQRI recommendation for OINDP; however, the value could differ for other dosage forms.):




Extractables above the AET should be evaluated, but extractables below the AET are of no significant safety or toxicity concern.

Step 3: Design Combined Extractables and Leachables Study. For extraction solvents, because the tubing has a relatively short contact time with the drug solution, only a placebo buffer and the product formulation are needed, plus an organic solvent, such as 20% ethanol, to cover a worst-case scenario. For analysis of metals, a dilute acidic solution is used.

The extraction temperature is 50 C for the placebo buffer and the 20% ethanol; the extraction time for both is 24 hours. Ambient conditions for the drug product formulation are for 1, 4, 8, and 24 hours (to obtain short-term compatibility and leachables information).

The remaining procedures for Step 3 are the same as those listed in case study 1.

Step 4: Extractables Evaluation. The analytical evaluation should include extractables and short-term leachables identity, amount, and potential TDI, as well as a toxicological evaluation. These evaluations can qualify or disqualify the tubing, based on extractables or leachables, from its intended use as bioprocess disposable tubing.

Step 5: Leachables Method Development and Validation. Leachables method development and validation may not be necessary because the tubing has a short contact time with the drug product formulation during the manufacturing process.

Step 6: Leachables Analysis of Stability Samples. Leachables analysis of long-term stability samples for tubing is not necessary. On the other hand, short-term tubing leachables information should be acquired and evaluated in parallel with extractables as described in Step 3.

Step 7: Leachables Trending, and Extractables and Leachables Correlation Analysis. Data acquired from Step 3 can be used for a leachables trending analysis and for the correlation of extractables and leachables.

The remaining steps (8 and 9) are the same as described in case study 1.

SUMMARY OF CASE STUDIES

E/L studies should be designed to achieve their intended purposes as demonstrated in case studies 1 and 2 for bags and tubing used in a disposable bioprocess. The data obtained through E/L studies designed for different materials and manufacturing processes can be compiled into a well-organized system, such as a library system, to increase scientific understanding and the knowledge base for future use.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here